Kyoto University has conducted a clinical study of administering platelets made from the patient's own iPS cells to patients with intractable diseases in which platelets, a component of the blood, are deficient. research group announced.
This was announced at an online press conference by a research group led by Professor Hiroyuki Eto of the Kyoto University iPS Cell Research Institute.
For the past four years, the group has been conducting clinical research into administering platelets made from iPS cells to a patient suffering from an intractable disease called aplastic anemia.
The patient's platelet type is extremely rare among Japanese people, and he could not receive blood transfusions from other people.
Three doses ranging from 20ml to 180ml were administered, and the progress was observed for one year.
In the future, the research group will continue to confirm the effectiveness of iPS cells, and hopes to lead to the practical use of blood transfusions that do not rely on blood donations using iPS cells.
Professor Eto said, "It is a great achievement that we were able to confirm the safety in the world's first clinical study. In the future, we would like to proceed with research toward the provision of platelets at low cost."